Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
- None.
- None.
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor)
DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA. The posters will cover ATRN-119, Aprea’s novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase.
| Presentation Details | |
| Title: | First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations |
| Presenter | Nadeem Q. Mirza, MD, MPH |
| Session Title: | First-in-Human Phase I Clinical Trials 2 |
| Date and Time: | Tuesday Apr 9, 9:00 AM - 12:30 PM PT |
| Location: | Poster Section 48 |
| Poster Board Number: | 23 |
| Abstract Presentation Number: | CT195 |
| Title: | First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors |
| Presenter | Nadeem Q. Mirza, MD, MPH |
| Session Title: | First-in-Human Phase I Clinical Trials 2 |
| Date and Time: | Tuesday Apr 9, 9:00 AM - 12:30 PM PT |
| Location: | Poster Section 48 |
| Poster Board Number: | 24 |
| Abstract Presentation Number: | CT196 |
| Title: | The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancers |
| Presenter: | Molly Hansbarger |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | DNA Damage and Repair Session |
| Date and Time: | Wednesday Apr 10, 9:00 AM - 12:30 PM PT |
| Location: | Poster Section 22 |
| Poster Board Number: | 16 |
| Published Abstract Number: | 7121 |
| Title: | Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma |
| Presenter: | Teresa Lee, Ph.D |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | DNA Damage and Repair |
| Session Date and Time: | Wednesday Apr 10, 9:00 AM - 12:30 PM PT |
| Location: | Poster Section 22 |
| Poster Board Number: | 12 |
| Published Abstract Number: | 7117 |
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our ability to continue as a going concern, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
What is the focus of the four poster presentations by Aprea Therapeutics, Inc. at the AACR Annual Meeting?
Who is presenting the first-in-human phase 1 study of WEE1 inhibitor APR-1051?
What is the potential of APR-1051 according to the poster presentations?
What is the synergistic effect mentioned in one of the poster presentations?
